480 related articles for article (PubMed ID: 12860911)
1. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.
Sattar N; Gaw A; Scherbakova O; Ford I; O'Reilly DS; Haffner SM; Isles C; Macfarlane PW; Packard CJ; Cobbe SM; Shepherd J
Circulation; 2003 Jul; 108(4):414-9. PubMed ID: 12860911
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
[TBL] [Abstract][Full Text] [Related]
3. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study.
Onat A; Uyarel H; Hergenç G; Karabulut A; Albayrak S; Can G
Atherosclerosis; 2007 Mar; 191(1):182-90. PubMed ID: 16678831
[TBL] [Abstract][Full Text] [Related]
4. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.
Sattar N; Scherbakova O; Ford I; O'Reilly DS; Stanley A; Forrest E; Macfarlane PW; Packard CJ; Cobbe SM; Shepherd J;
Diabetes; 2004 Nov; 53(11):2855-60. PubMed ID: 15504965
[TBL] [Abstract][Full Text] [Related]
5. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.
Lorenzo C; Okoloise M; Williams K; Stern MP; Haffner SM;
Diabetes Care; 2003 Nov; 26(11):3153-9. PubMed ID: 14578254
[TBL] [Abstract][Full Text] [Related]
6. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.
Alexander CM; Landsman PB; Teutsch SM; Haffner SM; ;
Diabetes; 2003 May; 52(5):1210-4. PubMed ID: 12716754
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes.
Tong PC; Kong AP; So WY; Yang X; Ho CS; Ma RC; Ozaki R; Chow CC; Lam CW; Chan JC; Cockram CS
Diabetes Care; 2007 May; 30(5):1206-11. PubMed ID: 17259472
[TBL] [Abstract][Full Text] [Related]
8. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
Circulation; 1998 Apr; 97(15):1440-5. PubMed ID: 9576423
[TBL] [Abstract][Full Text] [Related]
9. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors.
Sacks FM; Tonkin AM; Craven T; Pfeffer MA; Shepherd J; Keech A; Furberg CD; Braunwald E
Circulation; 2002 Mar; 105(12):1424-8. PubMed ID: 11914249
[TBL] [Abstract][Full Text] [Related]
10. Comparison of coronary heart disease risk assessments among individuals with metabolic syndrome using three diagnostic definitions: a cross-sectional study from China.
Zhou J; Gao Q; Wang J; Zhang M; Ma J; Wang C; Chen H; Peng X; Hao L
BMJ Open; 2018 Oct; 8(10):e022974. PubMed ID: 30366915
[TBL] [Abstract][Full Text] [Related]
11. Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
Rana JS; Visser ME; Arsenault BJ; Després JP; Stroes ES; Kastelein JJ; Wareham NJ; Boekholdt SM; Khaw KT
Int J Cardiol; 2010 Sep; 143(3):399-404. PubMed ID: 19394708
[TBL] [Abstract][Full Text] [Related]
12. Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis.
Malik S; Zhao Y; Budoff M; Nasir K; Blumenthal RS; Bertoni AG; Wong ND
JAMA Cardiol; 2017 Dec; 2(12):1332-1340. PubMed ID: 29117273
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes.
Gurka MJ; Guo Y; Filipp SL; DeBoer MD
Cardiovasc Diabetol; 2018 Jan; 17(1):17. PubMed ID: 29351794
[TBL] [Abstract][Full Text] [Related]
14. Prediction of coronary heart disease using risk factor categories.
Wilson PW; D'Agostino RB; Levy D; Belanger AM; Silbershatz H; Kannel WB
Circulation; 1998 May; 97(18):1837-47. PubMed ID: 9603539
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.
Freeman DJ; Norrie J; Caslake MJ; Gaw A; Ford I; Lowe GD; O'Reilly DS; Packard CJ; Sattar N;
Diabetes; 2002 May; 51(5):1596-600. PubMed ID: 11978661
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
Freeman DJ; Norrie J; Sattar N; Neely RD; Cobbe SM; Ford I; Isles C; Lorimer AR; Macfarlane PW; McKillop JH; Packard CJ; Shepherd J; Gaw A
Circulation; 2001 Jan; 103(3):357-62. PubMed ID: 11157685
[TBL] [Abstract][Full Text] [Related]
17. Global coronary heart disease risk assessment of individuals with the metabolic syndrome in the U.S.
Hoang KC; Ghandehari H; Lopez VA; Barboza MG; Wong ND
Diabetes Care; 2008 Jul; 31(7):1405-9. PubMed ID: 18375418
[TBL] [Abstract][Full Text] [Related]
18. Associations of a metabolic syndrome severity score with coronary heart disease and diabetes in fasting vs. non-fasting individuals.
DeBoer MD; Filipp SL; Gurka MJ
Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):92-98. PubMed ID: 31662283
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort.
Bataille V; Perret B; Dallongeville J; Arveiler D; Yarnell J; Ducimetière P; Ferrières J
Diabetes Metab; 2006 Nov; 32(5 Pt 1):475-9. PubMed ID: 17110903
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients.
Mayer O; Bruthans J; Seidlerová J; Karnosová P; Vaněk J; Hronová M; Gelžinský J; Cvíčela M; Wohlfahrt P; Cífková R; Filipovský J
Eur J Intern Med; 2018 Jan; 47():55-61. PubMed ID: 28755847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
